Clostridioides difficile (C. diff) is the leading cause of antibiotic-associated colitis. Here, we report that lemon exosome-like nanoparticles (LELNs) manipulated probiotics to inhibit C. diff infection (CDI). LELN-manipulated Lactobacillus rhamnosus GG (LGG) and Streptococcus thermophilus ST-21 (STH) (LELN-LS) decrease CDI mortality via an LELN-mediated increase in bile resistance and gut survivability. LELN-LS treatment increases the AhR ligands indole-3-lactic acid (I3LA) and indole-3-carboxaldehyde (I3Ald), leading to induction of IL-22, and increases lactic acid leading to a decrease of C. diff fecal shedding by inhibiting C. diff growth and indole biosynthesis. A synergistic effect between STH and LGG was identified. The STH metabolites inhibit gluconeogenesis of LGG and allow fructose-1,6-bisphosphate (FBP) to accumulate in LGG; accumulated FBP then activates lactate dehydrogenase of LGG (LGG-LDH) and enhances production of lactic acid and the AhR ligand. Our findings provide a new strategy for CDI prevention and treatment with a new type of prebiotics.
Commensal bacteria produce a diverse array of glycosylated molecules, including glycoproteins, glycolipids, peptidoglycan, capsular polysaccharides, and exopolysaccharides, which play fundamental roles in host-microbe interactions. Recent advances have highlighted the intricate mechanisms by which bacterial glycosylation contributes to immune regulation, epithelial barrier integrity, and microbial community stability, with implications for a range of conditions, including infectious diseases, chronic inflammatory disorders such as inflammatory bowel disease (IBD) and Alzheimer's disease, and metabolic diseases such as diet-induced obesity. This review provides a comprehensive synthesis of historical and recent insights into commensal bacterial glycosylation, emphasizing its role as a key mediator of host-bacteria interactions and its broader impact on gut homeostasis and systemic health.
Fungal and bacterial dysbiosis are linked to asthma disease severity, yet how overgrowth of the commensal fungus Candida albicans contributes to disease progression is not fully understood. Here, we show that intestinal aryl hydrocarbon receptor (AhR) deficiency exacerbates house dust mite (HDM)-induced allergic airway disease (AAD) during oral Candida albicans colonization through enhanced IL-17 responsiveness and lung structural cell fucosylation. Intestinal AhR deficiency promotes exaggerated IL-17 responses that promotes neutrophil migration and accumulation in the lung and reshapes the gut microbiota, particularly reducing the abundance of Akkermansia muciniphila. Concurrently, increased fucosylation of lung structural cells enhances L-selectin glycan ligand biosynthesis, thereby promoting neutrophil adhesion and retention within inflamed lung tissue. These adherent neutrophils lead to mitochondrial dysfunction, oxidative stress, and tissue injury in epithelial and endothelial compartments. Administration of A. muciniphila or its derived outer membrane vesicles (OMVs), as well as genetic deletion of Fut2, reduces lung fucosylation, suppresses neutrophil adhesion and NET formation, and attenuates Candida albicans–exacerbated AAD. Together, these findings show that intestinal AhR signaling remotely regulates an IL-17- gut microbiota-fucosylation axis that promotes neutrophil adhesion, mitochondrial dysfunction of lung structure cell, and neutrophilic airway inflammation during Candida albicans–associated asthma.
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal disorders that pose significant threats to human health and share common pathological features, including intestinal mucosal barrier disruption and gut microbiota dysbiosis, in which fucosylation acts as a critical regulatory mediator. Fucosylation is a highly conserved post-translational glycosylation modification involving the enzymatic transfer of fucose residues to glycoproteins and glycolipids. This tightly regulated process plays essential roles in maintaining intestinal homeostasis, mediating host–microbiota interactions and regulating immune responses. This review adopts a physiology-to-pathology framework, delineating fucosylation’s operational principles in healthy intestines and its dysregulation in IBD and CRC. It summarizes the spatial distribution of fucosylation, its regulatory mechanisms, and its roles in disease pathogenesis, and also discusses its potential as a diagnostic biomarker and therapeutic target. Finally, this review highlights future research directions to bridge mechanistic insights with clinical translation, emphasizing the promise of fucosylation in the precision diagnosis and treatment of intestinal disorders.